Oncology Clinical Trial Site Networks: Accelerating Cancer Research
The landscape of oncology clinical trials depends on well-organized site networks that connect pharmaceutical sponsors with qualified investigators and patient populations. With over 2,100 oncology trials initiated globally in 2024 alone, selecting the right site network is a critical factor in achieving enrollment targets on time and within budget.
The Role of Site Networks in Oncology Trials
Site networks aggregate independent investigators, academic medical centers, and community oncology practices under a shared operational framework. This structure offers sponsors several advantages:
- Faster site activation — Networks with pre-qualified sites and master agreements can cut startup timelines by weeks. Precision Site Network reports 26% faster IRB/EC approval at member sites.
- Broader patient access — Community-based networks like Sarah Cannon Research Institute reach patient populations outside major academic centers, which is essential for trials requiring diverse enrollment.
- Centralized operations — Regulatory submissions, monitoring, and data management are streamlined when working through a network rather than engaging sites individually.
Key Network Models
- Academic Cooperative Groups
- Organizations like NRG Oncology (1,000+ sites across five continents) focus on NCI-funded Phase II/III trials. They bring together radiation oncology, surgical oncology, and gynecologic oncology under a unified protocol infrastructure descended from legacy groups NSABP, RTOG, and GOG.
- Community-Based SMOs
- Networks such as Sarah Cannon Research Institute (250+ sites in 24 US states) and OneOncology (565+ locations in 15 states) operate as site management organizations that bring clinical trials directly to community practices. SCRI alone has contributed to the development of more than 100 FDA-approved cancer therapies.
- Early-Phase Specialist Networks
- NEXT Oncology and the START Center for Cancer Research focus exclusively on Phase I first-in-human trials. START's global network of eight sites has conducted over 1,300 Phase I oncology trials, contributing to 43 FDA/EMA-approved therapies.
Geographic Considerations
North America accounts for over 41% of oncology clinical trial activity, but site networks are expanding globally. China has become the leading site for early-phase and validation-phase trials, and networks like Precision Site Network now cover 53 North American, 50 European, and 3 Asia-Pacific sites across 15 countries. Sponsors planning multinational oncology studies should evaluate network coverage against their target indications and regulatory requirements in each region.
Evaluating Network Fit
| Criteria | What to Assess |
|---|---|
| Tumor type expertise | Does the network have investigators experienced in your specific indication (e.g., NSCLC, breast, hematologic malignancies)? |
| Phase capability | Phase I dose-escalation requires different infrastructure than Phase III registration trials |
| Patient access | Enrollment feasibility based on the network's catchment population and competitive landscape |
| Regulatory track record | Central IRB capabilities, IND experience, and inspection readiness |
| Data quality | Historical protocol deviation rates, query resolution times, and audit findings |